6-(dihydroxymethylidene)-4,5-dioxopyran-2-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃
• 英文名称: 6-(dihydroxymethylidene)-4,5-dioxopyran-2-carboxylic acid
• 化学式: C₇H₄O₇
• 分子量: 200.1
• InChiKey: SELRUPTWVICDPZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  121
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• CONJUGATE-BASED ANTIFUNGAL AND ANTIBACTERIAL PRODRUGS
  申请人：Bapat Abhijit S.

  公开号：US20140364595A1

  公开（公告）日：2014-12-11

  The invention provides conjugate-based antifungal or antibacterial prodrugs formed by coupling at least one anti-fungal agent or antibacterial agent with at least one linker and/or carrier. The prodrugs are of formula: (i) (AFA) m -X-(L) n ; (ii) [(AFA) m′ -X] p -L; (iii) AFA-[X-(L) n′ ] q ; or (iv) (AFA) m″ -X, wherein: AFA is an antifungal agent or an antibacterial agent; L is a carrier; X is a linker; m ranges from 1 to 10; n ranges from 2 to 10; m′ is 1 to 10; p is 1 to 10; n′ is 1 to 10; and q is 1 to 10, provided that q′ and n are not both 1; and m″ is 1 to 10. The invention also provides nanoparticles comprising the conjugate-based prodrugs. Additionally, the invention also provides non-conjugated antifungal and antibacterial agents in the form of nanoparticles.

  该发明提供了由至少一种抗真菌剂或抗菌剂与至少一种连接剂和/或载体偶联形成的基于共轭的抗真菌或抗菌前药。这些前药的公式为：(i) (AFA) m -X-(L) n ; (ii) [(AFA) m′ -X] p -L; (iii) AFA-[X-(L) n′ ] q ; 或 (iv) (AFA) m″ -X，其中：AFA是抗真菌剂或抗菌剂；L是载体；X是连接剂；m范围从1到10；n范围从2到10；m′为1到10；p为1到10；n′为1到10；q为1到10，前提是q'和n不同时为1；m″为1到10。该发明还提供了包含基于共轭的前药的纳米粒子。此外，该发明还提供了以纳米粒子形式的非共轭抗真菌和抗菌剂。
• [EN] NOVEL COMPOUNDS AND METHODS OF USING THEM<br/>[FR] COMPOSÉS NOVATEURS ET PROCÉDÉS D'UTILISATION DE CEUX-CI
  申请人：SYNDAX PHARMACEUTICALS INC

  公开号：WO2009015203A1

  公开（公告）日：2009-01-29

  Described herein are novel HDAC modulators, formulations containing them and methods of using them. In some embodiments, the HDAC modulators possess specific stereo chemistry. In other embodiments, the compounds described herein are used in the treatment or prevention of histone deacetylase mediated disorders.

  本文描述了新型HDAC调节剂，含有它们的配方以及使用它们的方法。在某些实施例中，HDAC调节剂具有特定的立体化学结构。在其他实施例中，本文描述的化合物用于治疗或预防组蛋白去乙酰化酶介导的疾病。
• [EN] METHODS FOR HYDRAULIC ENHANCEMENT OF CROPS<br/>[FR] PROCÉDÉS DE STIMULATION HYDRAULIQUE DES CULTURES
  申请人：ASILOMAR BIO INC

  公开号：WO2016172655A1

  公开（公告）日：2016-10-27

  Disclosed herein are compounds, salts, solvates of Formula (1), and any formulation thereof. Also disclosed are methods of eliciting hydraulic enhancement and/or increasing yield of a plant by contacting a plant with compounds, salts, solvates of Formula (1), or any formulation thereof.

  本文披露了化合物、盐、溶剂化合物的化合物（1）及其任何配方。还披露了通过将植物与化合物、盐、溶剂化合物的化合物（1）或其任何配方接触来引发水力增强和/或增加植物产量的方法。
• [EN] PROCESS<br/>[FR] PROCÉDÉ
  申请人：IRON THERAPEUTICS HOLDINGS AG

  公开号：WO2012101442A1

  公开（公告）日：2012-08-02

  The invention provides a method of forming an iron hydroxypyrone compound comprising reacting a hydroxypyrone with a non-carboxylate iron salt in an aqueous solution, and precipitating the iron hydroxypyrone compound from the aqueous solution having a pH of greater than 7.

  本发明提供了一种制备铁羟基吡酮化合物的方法，包括在水溶液中将羟基吡酮与非羧酸铁盐反应，并从pH大于7的水溶液中沉淀出铁羟基吡酮化合物。
• [EN] METHOD OF FORMING IRON HYDROXYPYRONE COMPOUNDS<br/>[FR] METHODE DE FORMATION DE COMPOSES D'HYDROXYPYRONE DE FER
  申请人：VITRA PHARMACEUTICALS LTD

  公开号：WO2003097627A1

  公开（公告）日：2003-11-27

  A method of forming an iron hydroxypyrone compound comprising reacting an iron salt of a carboxylic acid and a hydroxypyrone in an aqueous solution at a pH greater than 7.

  一种形成铁羟基吡酮化合物的方法，包括在pH大于7的水溶液中反应羧酸铁盐和羟基吡酮。